HY-2019

HY-2019 is a novel small molecule Janus kinase (JAK) inhibitor developed by West China Hospital of Sichuan University, specifically designed for the treatment of hair loss conditions such as androgenetic alopecia. Formulated as a topical tincture, the drug is intended to provide localized therapeutic effects while minimizing systemic side effects. HY-2019 functions by inhibiting JAK3 and members of the TEC kinase family, which are involved in the inflammatory signaling pathways that contribute to hair follicle miniaturization. By modulating these pathways, the treatment aims to suppress follicular inflammation and stimulate the transition of hair follicles into the anagen (growth) phase, thereby promoting hair density and regrowth. It is currently undergoing clinical evaluation in China to assess its safety and efficacy in patients with pattern hair loss.

Other names

HY-2019 TinctureHY2019 TinctureHY 2019 Tincture